AEON Biopharma, Inc. (AEON)
| Market Cap | 267.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.60M |
| Shares Out | 37.16M |
| EPS (ttm) | 0.57 |
| PE Ratio | 12.63 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,445 |
| Open | 7.30 |
| Previous Close | 7.02 |
| Day's Range | 6.73 - 7.71 |
| 52-Week Range | 3.37 - 11.88 |
| Beta | -0.03 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+150.0%) |
| Earnings Date | Feb 11, 2024 |
About AEON
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AEON stock is "Strong Buy" and the 12-month stock price forecast is $18.0.
News
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
– Expect to announce topline data in Q3 2024 – – Company plans in Q1 2024 an end-of-phase 2 meeting with the FDA to discuss the Phase 3 program in episodic migraine – – Anticipate shortening the open ...
AEON Biopharma Reports Third Quarter 2023 Financial Results
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study –
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not me...
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary b...
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary b...
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
The 7,380,394 AEON shares reflected in the Form 4 filed on August 14 th were transferred to limited partners of Strathspey Crown
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively.